Medicus Pharma is repositioning as a precision oncology biotech, prioritizing its cancer drug candidate CD228V targeting CD228-expressing solid tumors, with initial clinical trials focused on melanoma. The company sees melanoma, especially relapsed or refractory cases, as a key development area, supported by ongoing Phase 1 studies and regulatory approvals. Medicus is also narrowing its SkinJect program to treat Gorlin syndrome, a rare disease, aiming for FDA orphan drug status, while advancing Teverelix in urinary retention and endometriosis, with potential partnerships for prostate cancer. This strategic shift aims to concentrate resources on high-value programs and enhance long-term growth in oncology.
Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...
ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...
GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
